James Jiao

834 total citations
18 papers, 628 citations indexed

About

James Jiao is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James Jiao has authored 18 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Genetics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James Jiao's work include Chronic Lymphocytic Leukemia Research (8 papers), Prostate Cancer Treatment and Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). James Jiao is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Prostate Cancer Treatment and Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). James Jiao collaborates with scholars based in United States, Belgium and Spain. James Jiao's co-authors include Peter Hellemans, Margaret K. Yu, Michael D. Voigt, Caly Chien, Wolfgang Vogel, Lewis Teperman, Cosme Manzarbeitia, Paul Martin, Naga Chalasani and Juan Carlos López-Talavera and has published in prestigious journals such as Blood, Hepatology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

James Jiao

18 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Jiao United States 13 197 193 144 139 115 18 628
Marta Spreafico Italy 19 140 0.7× 158 0.8× 157 1.1× 80 0.6× 52 0.5× 38 976
Barbara J. Brennan United States 13 169 0.9× 164 0.8× 100 0.7× 42 0.3× 13 0.1× 41 530
Akihiro Deguchi Japan 15 385 2.0× 233 1.2× 147 1.0× 66 0.5× 20 0.2× 41 681
Soo Ryang Kim Japan 15 500 2.5× 472 2.4× 95 0.7× 61 0.4× 32 0.3× 87 880
Zeid Kayali United States 16 762 3.9× 1.0k 5.3× 200 1.4× 126 0.9× 305 2.7× 33 1.5k
Subhash Chander India 15 32 0.2× 140 0.7× 62 0.4× 112 0.8× 24 0.2× 71 673
Xianbin Tian United States 19 64 0.3× 118 0.6× 216 1.5× 40 0.3× 51 0.4× 33 972
J Nataf France 11 110 0.6× 136 0.7× 264 1.8× 81 0.6× 17 0.1× 15 1.3k
Sander Bins Netherlands 17 44 0.2× 113 0.6× 376 2.6× 324 2.3× 43 0.4× 59 1.2k
Sharon Diamond United States 12 123 0.6× 63 0.3× 348 2.4× 95 0.7× 14 0.1× 21 1.0k

Countries citing papers authored by James Jiao

Since Specialization
Citations

This map shows the geographic impact of James Jiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Jiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Jiao more than expected).

Fields of papers citing papers by James Jiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Jiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Jiao. The network helps show where James Jiao may publish in the future.

Co-authorship network of co-authors of James Jiao

This figure shows the co-authorship network connecting the top 25 collaborators of James Jiao. A scholar is included among the top collaborators of James Jiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Jiao. James Jiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Durán, Ignacio, Joan Carles, Iurie Bulat, et al.. (2020). Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics. 59(9). 1135–1148. 42 indexed citations
3.
Jong, Jan de, Wojciech Jurczak, Raúl Córdoba, et al.. (2020). Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. Pharmacology Research & Perspectives. 8(5). e00649–e00649. 1 indexed citations
4.
Poggesi, Italo, Lilian Y. Li, James Jiao, et al.. (2019). Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study. European Journal of Drug Metabolism and Pharmacokinetics. 45(1). 101–111. 16 indexed citations
5.
Jong, Jan de, Nahor Haddish‐Berhane, Peter Hellemans, et al.. (2018). The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemotherapy and Pharmacology. 82(2). 299–308. 8 indexed citations
6.
Wit, Ronald de, Caly Chien, Peter Hellemans, et al.. (2018). An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 82(3). 457–468. 22 indexed citations
7.
Jong, Jan de, Peter Hellemans, Tara Masterson, et al.. (2018). A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & lymphoma. 59(12). 2888–2895. 33 indexed citations
8.
Jong, Jan de, Peter Hellemans, James Jiao, et al.. (2017). Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study. Cancer Chemotherapy and Pharmacology. 80(6). 1227–1237. 22 indexed citations
9.
Jong, Jan de, Donna Skee, Peter Hellemans, et al.. (2016). Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*. Leukemia & lymphoma. 58(1). 185–194. 17 indexed citations
10.
Jong, Jan de, Peter Hellemans, Tara Masterson, et al.. (2016). A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy. Blood. 128(22). 3964–3964. 1 indexed citations
11.
Jong, Jan de, Peter Hellemans, James Jiao, Juthamas Sukbuntherng, & Danièle Ouellet. (2016). An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults. Blood. 128(22). 1588–1588. 3 indexed citations
12.
N., Kim, Jennifer L. Spratlin, Christian Kollmannsberger, et al.. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology. 55(12). 1406–1414. 82 indexed citations
13.
Vries, Ronald de, Johan W. Smit, Peter Hellemans, et al.. (2015). Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. British Journal of Clinical Pharmacology. 81(2). 235–245. 58 indexed citations
14.
Inoue, Kouichi, Akira Shishido, Nicole Vaccaro, et al.. (2014). Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing. Cancer Chemotherapy and Pharmacology. 75(1). 49–58. 15 indexed citations
15.
Vaccaro, Nicole, Milin Acharya, James Jiao, et al.. (2014). Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin. Clinical Pharmacology in Drug Development. 4(1). 63–73. 29 indexed citations
16.
Auchus, Richard J., Elizabeth Buschur, Alice Y. Chang, et al.. (2014). Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 99(8). 2763–2770. 60 indexed citations
17.
Marbury, Thomas, Eric Lawitz, Martha Gonzalez, et al.. (2013). Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. The Journal of Clinical Pharmacology. 54(7). 732–741. 23 indexed citations
18.
Chalasani, Naga, Cosme Manzarbeitia, Peter Ferenci, et al.. (2005). Peginterferon alfa‐2a for hepatitis C after liver transplantation. Hepatology. 41(2). 289–298. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Spreafico Breakdown of academic impact, for papers by Barbara J. Brennan Breakdown of academic impact, for papers by Akihiro Deguchi Breakdown of academic impact, for papers by Soo Ryang Kim Breakdown of academic impact, for papers by Zeid Kayali Breakdown of academic impact, for papers by Subhash Chander Breakdown of academic impact, for papers by Xianbin Tian Breakdown of academic impact, for papers by J Nataf Breakdown of academic impact, for papers by Sander Bins Breakdown of academic impact, for papers by Sharon Diamond
Rankless by CCL
2026